Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis [PDF]
Cancer Medicine, 2019 Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease‐related symptoms in patients with myelofibrosis (MF).
Novella Pugliese +14 more
doaj +2 more sources
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial [PDF]
Journal of Hematology & Oncology, 2017 Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Srdan Verstovsek +21 more
doaj +3 more sources
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I [PDF]
Haematologica, 2015 In the phase III COMFORT-I study, the Janus kinase 1 (JAK1)/JAK2 inhibitor ruxolitinib provided significant improvements in splenomegaly, key symptoms, and quality-of-life measures and was associated with an overall survival benefit relative to placebo ...
Srdan Verstovsek +21 more
doaj +3 more sources
Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study [PDF]
Annals of HematologyChronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by
Yuqing Tu +23 more
doaj +2 more sources
Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report [PDF]
Case Reports in Oncological MedicineRuxolitinib is a Janus kinase inhibitor that has been associated with lipid abnormalities, including a 15% incidence of hypertriglyceridemia. We describe a case of a 37-year-old man with refractory T-cell lymphoma treated with ruxolitinib for ...
Sarah Medina +8 more
doaj +2 more sources
Acute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report [PDF]
Annals of HematologyPolycythaemia vera (PV) is a myeloproliferative neoplasm (MPN) which can progress to myelofibrosis (MF), a phenomenon termed post-PV MF. Ruxolitinib is a Janus activated kinase (JAK) inhibitor that targets JAK1/2 mutations and is approved for treatment ...
Louise Jade Potter +2 more
doaj +2 more sources
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis [PDF]
New England Journal of Medicine, 2012 Ruben Mesa, Jason Gotlib, Vikas Gupta
exaly +3 more sources
c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]
PLoS ONE, 2014 The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan +3 more
doaj +1 more source
Blood Cancer Journal, 2023 The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy +18 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao +18 more
doaj +1 more source